Last reviewed · How we verify

NCT06192901

Safety and Performance of Hydrophobic and Hydrophilic Intraocular Lenses After Bilateral Cataract Surgery

Completed Last updated 5 January 2024
What this trial tests

trial in Senile Cataract in 8 participants. Completed in 22 September 2023.

Timeline
18 September 2023
Primary endpoint
22 September 2023
22 September 2023

Quick facts

Lead sponsorCarl Zeiss Meditec AG
StatusCompleted
Study typeOBSERVATIONAL
Enrollment8
Start date18 September 2023
Primary completion22 September 2023
Estimated completion22 September 2023
Sites1 location across El Salvador

Conditions studied

Sponsor

Carl Zeiss Meditec AG — full company profile →

Who can join

18 and older, any sex, with Senile Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Subjects who had a bilateral age-related cataract surgery with the IOLs AT ELANA 841P and AT LISA tri 839MP will be contacted and invited to attend a postoperative visit more than one year after the surgery

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Carl Zeiss Meditec AG trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06192901.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing